Skip to main content
. 2007 May 16;81(14):7410–7423. doi: 10.1128/JVI.00505-07

FIG. 3.

FIG. 3.

Homologous and heterologous neutralization of recombinant SARS-CoV spike glycoprotein variants by mouse monoclonal antibodies and human convalescent-phase sera. Serial diluted samples of mouse monoclonal antibodies (341CD, 540CD, and 283CD) and seven convalescent human serum samples from SARS cases (Human sera) were tested for the neutralizing ability of 100 PFU of different recombinant SARS-CoV spike glycoprotein variants (icUrbani, icCUHK-W1, icGZ02, icHC/SZ/61/03, and icA031G) as described in Materials and Methods. Results are expressed as the dilution of antibody at which 50% of the viruses are neutralized. Error bars represent standard deviations.